VolitionRX (VNRX) Projected to Announce Earnings on Thursday

VolitionRX (NYSEAMERICAN:VNRX) is anticipated to issue its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect VolitionRX to post earnings of ($0.35) per share and revenue of $0.71 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 8:30 AM ET.

VolitionRX (NYSEAMERICAN:VNRX) last released its earnings results on Thursday, August 13th. The medical research company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.41 million.

VolitionRX Trading Up 2.1%

Shares of NYSEAMERICAN VNRX opened at $0.20 on Tuesday. VolitionRX has a one year low of $0.16 and a one year high of $8.13. The firm’s 50 day simple moving average is $0.24 and its two-hundred day simple moving average is $2.03.

Wall Street Analyst Weigh In

Separately, Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a research note on Monday, August 17th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, VolitionRX has a consensus rating of “Hold” and a consensus price target of $28.00.

About VolitionRX

VolitionRx Limited is a biotechnology company developing blood-based diagnostic tests intended to support the early detection and management of disease. Its technology platform, Nu.Q, analyzes nucleosomes—small structures released into the bloodstream when cells die—to identify biological signals associated with cancer and other conditions.

The company’s products and development programs serve human and veterinary health markets. Its Nu.Q Vet platform is designed to help veterinarians screen for and monitor cancer in companion animals, while the company is also developing Nu.Q-based applications for human cancer, infectious diseases, and other medical conditions.